Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

ONCY Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Oncolytics Biotech Inc.NASDAQ: ONCY

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns negative

Q1 FY2026 accounts payables was -CA$1.13M, compared with CA$0 a year earlier. Trailing-twelve-month accounts payables was -CA$1.13M.

Context

  • Accounts payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near -CA$1.13M or moves back toward the trailing-twelve-month quarterly average of -CA$283.45K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$1.13M— QoQ
Last fiscal yearDec 2025
CA$0— YoY
LTMMar 2026
-CA$1.13M— YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

CAD · from the cash flow

Latest · FY2025
0 CAD
Year-over-year change
—

Accounts Payables vs competitors

How ONCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
ONCY Competitors
Accounts Payables for ONCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$12.77M USD+201.6%——
MGNXMacroGenics, Inc.LTM Mar 2026$2.31M USD-48.2%-70.5%1.5%
IMMXImmix Biopharma, Inc.LTM Mar 2026$1.2M USD-56.1%-3.2%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$1.13M CAD———
COYACoya Therapeutics, Inc.LTM Mar 2026$783.6K USD-867.8%—9.9%
TILInstil Bio, Inc.LTM Mar 2026$509K USD+153.5%——
SRZNSurrozen, Inc.LTM Mar 2026$307K USD+89.5%—4.1%
CLNNClene Inc.LTM Mar 2026$104K USD-55.2%—77.6%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$0 USD——0.0%
Peer median (excluding ONCY) —-48.2%-36.8%4.1%

Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.3M)(24.84M)(27.75M)(31.71M)(39.46M)
Depreciation & Amortization452.07K392K403K424K96.05K
Deferred Income Tax408.56K0000
Stock-Based Compensation3.83M2.38M2.07M2.72M4.26M
Change in Working Capital(907.99K)391K1.77M3.54M1.62M
Accounts Receivables(776.39K)345K506K(53K)4.03M
Inventory00000
Accounts Payables00000
Other Working Capital(131.59K)46K1.26M3.59M(2.41M)
Other Non-Cash Items91.73K(1.68M)(4.93M)(1.94M)5.89M
Operating Cash Flow(22.43M)(23.36M)(28.45M)(26.97M)(27.6M)
Capital Expenditures(285.95K)(55K)(8K)(239K)(8.23K)
Acquisitions (Net)00000
Purchases of Investments0(20.35M)000
Sales of Investments0020.23M00
Other Investing Activities0(20.35K)000
Investing Cash Flow(285.95K)(20.4M)20.22M(239K)(8.23K)
Debt Repayment(366K)(381K)(407K)(348K)0
Common Stock Issued32.91M12.57M31.62M6.92M19.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities469.68K12K781K65K(37.05K)
Financing Cash Flow33.02M12.21M31.99M6.64M19.37M
Effect of Forex Changes(253.25K)1.96M(522K)1.6M166.03K
Net Change in Cash10.04M(29.6M)23.25M(18.97M)(8.06M)
Free Cash Flow(22.72M)(23.41M)(28.46M)(27.21M)(27.6M)

Oncolytics Biotech Inc.

NASDAQ:ONCY

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.